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297Percutaneous Left Atrial Appendage Occlusion for
Stroke Prophylaxis in Nonvalvular Atrial Fibrillation
A Systematic Review and Analysis of Observational StudiesObjectives The goal of this study was to provide a systematic review and analysis of observational studies on percutaneous left
atrial appendage (LAA) occlusion for stroke prophylaxis in nonvalvular atrial ﬁbrillation (NVAF).
Background A recent randomized controlled trial in patients with NVAF suggested noninferiority of percutaneous LAA occlusion
versus medical management for stroke prevention. However, the use of percutaneous devices remains controversial because of
limited literature on their efﬁcacy and safety. We performed a systematic analytical review of existing observational studies to assess
the rate of neurological events for patients treated with occlusion devices.
Methods A comprehensive search of the Medline, Scopus, and Web of Science databases from inception through August 1, 2013,
was conducted using pre-deﬁned criteria. We included studies reporting implantation in at least 10 patients and a follow-up of
6 months or more.
Results In 17 eligible studies, a total of 1,052 devices were implanted in 1,107 patients with 1,586.4 person-years (PY) of follow-up.
The adjusted incidence rate of stroke was 0.7/100 PY (95% conﬁdence interval [CI]: 0.3 to 1.1/100 PY), of transient ischemic attacks
was 0.5/100 PY (95% CI: 0.1 to 1.8/100 PY), and of combined neurological events (strokes or transient ischemic attacks) was 1.1/100
PY (95% CI: 0.6 to 1.6/100 PY). Access site vascular complications and pericardial effusion were the most commonly observed
procedural complications at a rate of 8.6% (95% CI: 6.3% to 11.7%) and 4.3% (95% CI: 3.1% to 5.9%), respectively.
Conclusions Our systematic review suggested comparable efﬁcacy of LAA occlusion devices compared with historical controls treated
with adjusted-dose warfarin and other anticoagulation strategies for prevention of stroke in patients with NVAF. (J AmColl Cardiol Intv
2014;7:296–304)ª 2014 by the American College of Cardiology FoundationAtrial ﬁbrillation (AF) is the most common arrhythmia,
affecting more than 5.5 million people in the United States
alone (1–3). The lifetime risk of developing AF is reported
to be as high as 26% for men and 23% for women (4). Stroke
is a major contributor to morbidity and mortality among
the U.S. population, affecting almost 800,000 patients every
year. AF signiﬁcantly increases the risk of ischemic stroke
and is an underlying factor in up to 20% of total strokes
among the elderly (5).
The left atrial appendage (LAA) is a remnant structure
of the embryonic left atrium and persists as an out-pouching
of the adult left atrial chamber. In a ﬁbrillating atrium, the
LAA becomes a major site of blood stasis, which signiﬁcantly
increases the risk of clot formation. Indeed, almost 15% of
all patients with nonvalvular atrial ﬁbrillation (NVAF)
develop a thrombus in their heart, and transesophageal im-
aging studies have implicated the LAA as being the site for
thrombogenesis in>90% of these cases (6,7). For this reason,
stroke prophylaxis strategies and risk schema have been
developed to determine which patients are at the highest risk
for thromboembolic events. Therefore, anticoagulation with
adjusted-dose warfarin or the newer anticoagulants has been
offered to appropriate patients based on the accepted
CHADS2 (congestive heart failure, hypertension, age >75years, diabetes mellitus, and prior stroke or transient ischemic
attack) scoring system.However, anticoagulation increases the
risk of both intracerebral and extracranial bleeding, and
approximately 30% to 50% of patients with AF are ineligible
to receive anticoagulation (5,8).
More recently, percutaneous LAA occlusion devices have
been developed to overcome the aforementioned challenges
in thromboembolic prophylaxis in patients with NVAF. The
Percutaneous Left Atrial Appendage Transcatheter Occlu-
sion (PLAATO) device (Appriva Medical, Plymouth,
Minnesota) was the ﬁrst to be tested and used in humans.
Since then, multiple devices have emerged, including the
Amplatzer device (AGA Medical Corporation/St. Jude
Medical, Golden Valley, Minnesota), the Watchman device
(Boston Scientiﬁc, Natick, Massachusetts), and the
LARIAT suture delivery device (SentreHeart, Redwood
City, California) (9–11) (Fig. 1). The only reported ran-
domized clinical trial, PROTECT-AF (Watchman Left
Atrial Appendage System for Embolic Protection in Pa-
tients With Atrial Fibrillation), has demonstrated non-
inferiority of the Watchman device to adjusted-dose
warfarin therapy, and results from the CAP (Continued
Access Protocol) registry following up on this trial suggest a
decreasing trend of procedure-related complications as more
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298experience is gained with the technique (1,10). Although
multiple observational studies have assessed the efﬁcacy and
safety of this novel technique, large-scale comparative data
from clinical trials are not yet available. The results of the
PREVAIL (Prospective Randomized Evaluation of the
WATCHMAN LAA Closure Device in Patients With
Atrial Fibrillation Versus Long Term Warfarin Therapy)
study and the ongoing AMPLATZER Cardiac Plug
Clinical Trial are expected to produce more robust clinical
evidence once they are reported. To that end, we performed
a systematic statistical review of data pooled from the
currently available observational studies to estimate the
adjusted rates of stroke and major procedure-related com-
plications. This type of analysis has the strength to provide a
valuable estimate of the absolute effect of a particular
intervention in the real-world scenario when enoughAbbreviations
and Acronyms
AF = atrial ﬁbrillation
CHADS2 = congestive heart
failure, hypertension, age
>75 years, diabetes mellitus,
and prior stroke or transient
ischemic attack
CI = conﬁdence interval
LAA = left atrial appendage
NNT = number needed to
treat
NVAF = nonvalvular atrial
ﬁbrillation
PLAATO = Percutaneous Left
Atrial Appendage
Transcatheter Occlusion
PY = person-year(s)
TIA = transient ischemic
attackcomparator data from multiple
randomized controlled trials or
other comparative studies are not
available (12).
Methods
Search strategy. With the exper-
tise of a medical librarian, we
queried the Medline, Web of
Science, and SCOPUS data-
bases until August 1, 2013, for
eligible studies with the fol-
lowing list of MeSH (Medical
Subject Headings) terms: “atrial
ﬁbrillation,” “atrial append-
age,” “left atrial appendage,”
“atrial ﬁbrillation/prevention and
control,” “atrial ﬁbrillation/surgery,”
“atrial ﬁbrillation/therapy,” “non
valvular,” “percutaneous,” “mini-mally invasive,” “transcutaneous,” and “transcatheter.”
Study characteristics. All observational studies, including
case series and abstracts presented at scientiﬁc conferences,
were considered. Of these, studies that reported outcomes
after percutaneous closure in at least 10 patients with a
minimum of 6 months follow-up were included. In in-
stances where research groups reported cumulative results
from multiple publications, caution was exercised in data
extraction, and only studies with the largest sample size
and follow-up period for each outcome were included
(Fig. 1).
Outcome measures. The primary outcome was deﬁned as
the incidence of stroke in the follow-up period. Secondary
outcomes included transient ischemic attacks (TIAs) and
composite neurological events (deﬁned as the combination
of stroke and/or TIA) during the follow-up period. Safety
outcomes including procedure failures and procedural/device-related complications were also analyzed. Procedural/
device-related complications were deﬁned as any of the
following events: vascular access site hemorrhage, pericardial
effusion or tamponade, device embolization, procedural
mortality, and need for rescue cardiac surgery. Additionally,
several subgroup analyses were performed to deﬁne the de-
vice characteristics that may predict the occurrence of stroke/
TIA in the follow-up period. The number needed to treat
(NNT) for stroke prevention was also calculated using the
Newcombe-Wilson hybrid score (13).
Data extraction. The primary authors (N.S.B. and A.P.)
searched all titles and associated abstracts using the
described MeSH search strategy. Full-text papers for all
potentially relevant studies were retrieved and reviewed with
a primary focus on inclusion criteria, study outcomes, and
methodological quality. If the clinical study met the inclu-
sion criteria based on these 3 characteristics, it was included
in the analysis. The data from the studies were then
extracted using pre-designed structured forms and reviewed
by 2 authors (S.A. and N.S.) for accuracy and validity.
Disagreements, if any, were resolved by mutual consensus
between the authors.
Statistical analysis. After the data elements were veriﬁed for
accuracy, systematic and statistical analyses were conducted
using Comprehensive Meta-Analysis version 2 (Biostat,
Englewood, New Jersey) and SAS version 9.3 (SAS Insti-
tute, Cary, North Carolina), respectively. Because of a
relatively small proportion of primary events in each study,
the data were assumed to follow a Poisson distribution.
Pooled event rates (expressed as percentage per year) for the
efﬁcacy outcomes in the LAA arm and safety outcome rates
(per 100 procedures) were calculated using standard
methods. Fixed effects modeling was primarily utilized to
conduct systematic analysis of included studies. However,
we used random effects modeling in the case of statistically
signiﬁcant heterogeneity. Assessment of heterogeneity was
achieved by comparing the inclusion/exclusion criteria and
the minor differences in the design and conduct of the
studies. We assessed for heterogeneity using the I2 test (I2
>50% with p < 0.05 implies signiﬁcant heterogeneity). In
cases of signiﬁcant heterogeneity, the heterogeneity was ﬁrst
explored in the studies, and subsequently, analysis using a
random effects model was performed to statistically account
for the heterogeneity. Publication bias was assessed using the
funnel plot method and corrected using the Duval and
Tweedie trim and ﬁll method (14).
Subgroup analyses were performed to determine event
rates in different strata of the study population. All subgroup
analyses were pre-speciﬁed. All of the p values were 2-tailed,
with statistical signiﬁcance speciﬁed at p < 0.05 and con-
ﬁdence intervals (CIs) computed at the 95% level. The
analysis has been reported in accordance with the PRISMA
(Preferred Reporting Items for Systematic reviews and
Meta-Analyses) guidelines (15).
Figure 1. Devices Used for LAA Closure
(A) Amplatzer Cardiac Plug device. (B) Percutaneous Left Atrial Appendage Transcatheter Occlusion device. (C) Watchman device. (D) LARIAT device. LAA ¼ left atrial
appendage. Images were acquired from the websites of the following companies, with permission: Appriva Medical, AGA Medical Corporation/St. Jude Medical, Boston
Scientiﬁc, and SentreHeart.
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We included 17 observational studies (16–30) for the ﬁnal
analysis in accordance with study inclusion criteria (Fig. 2).
A total of 1,052 devices were implanted in 1,107 patients.
The pooled analysis yielded 1,586.4 person-years (PY) of
follow-up. Table 1 demonstrates the baseline characteristics
of the included studies. The follow-up varied from 7 to 29
months among the studies. The mean CHADS2 score was
2.7. Two studies had a mean CHADS2 score of <2, and
another 2 studies did not report CHADS2.
The predicted stroke rate varied between 2.5 and 5.3/100
PY, assuming a CHADS2 score of 3. Nine of 17 studies
reported post-procedural utilization of antiplatelet agents
(aspirin  clopidogrel) for varying time periods. There were
minor differences observed among inclusion and baseline
characteristics of included studies as demonstrated in
Table 1.
Efﬁcacy outcomes. The actual procedural success was 1,052
of 1,107 (95.1%). The adjusted procedural failure rate was
8.4% (95% CI: 6.6% to 10.6%) using random effects
modeling and adjusting for publication bias. The adjusted
pooled incidence rate of stroke in our systematic analyses
was 0.7/100 PY (95% CI: 0.3 to 1.1/100 PY) (Fig. 3). Therewas no publication bias to the right of mean, which was
assessed using the Duval and Tweedie trim and ﬁll method
(Fig. 4). Table 2 demonstrates subgroup analyses by device
type, year, and region; similar stroke rates were observed
in the Watchman and PLAATO devices of 0.7/100 PY
(95% CI: 0.0 to 1.5/100 PY) and 0.7/100 PY (95% CI: 0.0
to 1.6/100 PY), respectively, as compared with Amplatzer
0.9/100 PY (95% CI: 0.7 to 2.4/100 PY), although the
difference was not statistically signiﬁcant. There was no
statistically signiﬁcant difference observed in stroke rate over
the year or region (Table 2). The NNT for 1 stroke was
estimated at 21.7 (95% CI: 16.1 to 31.5) assuming a
CHADS2 score of 3 for the pooled population.
The adjusted rate of TIAs was observed to be 0.5/100 PY
(95% CI: 0.1 to 0.8/100 PY), with an estimated NNT of
23.3 (95% CI: 16.9 to 35.5). The pooled composite rate of
neurological events across all studies was found to be 1.1/100
PY (95% CI: 0.6 to 1.6/100 PY) (Fig. 2, Table 3) with a
NNT of 25.0 (95% CI: 17.7 to 40.4).
Safety outcomes. Tables 4 and 5 demonstrate the adjusted
pooled rates of periprocedural adverse events per 100 pro-
cedures observed across the studies. We calculated a com-
bined adverse event rate of 16.0% (95% CI: 13.6% to
18.7%). There were no statistically signiﬁcant differences in
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Subgroup analyses revealed a higher rate of combined
adverse events with both the Amplatzer and the Watchman
devices (23.5% [95% CI: 15.9% to 33.2%] and 13.6% [95%
CI: 9.7% to 18.8%], respectively), as compared with 5.4%
(95% CI: 3.5% to 8.2%) for PLAATO and 7.3% (95% CI:
2.7% to 18.3%) for LARIAT devices, although these were
not statistically signiﬁcant. The most frequent complication
was of the vascular access site: 8.6% (95% CI: 6.3% to
11.7%). The other frequently observed procedural compli-
cations were pericardial effusions and device embolization,
which occurred at a rate of 4.3% (95% CI: 3.1% to 5.9%)
and 3.9% (95% CI: 2.7% to 5.6%), respectively (Table 4).
Comparison with other anticoagulation strategies reported in
the literature. Figure 5 demonstrates the rates of ischemic
stroke despite therapeutic anticoagulation, as reported in theFigure 2. Flow Diagram Showing Selection of Studies for Analysis
EP ¼ electrophysiology; LAA ¼ left atrial appendage.literature. In our review, the stroke rate with percutaneous
LAA occlusion was estimated at 0.7/100 PY (95% CI: 0.2 to
1.2/100 PY), which is similar to recently reported results:
preliminary data of the PREVAIL study (31) (reporting a
stroke rate of 0.7/100 PY [95% CI: 0.1 to 5.1/100 PY]) and
the PROTECT-AF study (10) (2.2/100 PY [95% CI: 1.3 to
3.5/100 PY]) and to other anticoagulation strategies,
including adjusted-dose warfarin (32–35).
Discussion
Stroke prophylaxis poses a major challenge for patients
with NVAF who have contraindications to anticoagulation.
The LAA is the most common site for clot formation;
therefore, surgical ligation of the LAA is widely practiced
in patients undergoing open heart mitral valve surgery (36).
Table 1. Baseline Characteristics of Included Studies
First Author, Year (Ref. #)
Patients/
Devices
Follow-Up
(months) Device Used
Age
(yrs) CHADS2 Hypertension
Diabetes
Mellitus
Prior
Stroke
Congestive Heart
Failure
Ostermayer, 2005 (16) 111/108 9.8 PLAATO 71  9 2.5 80 (72.1) 29 (26.1) 42 (37.8) 43 (38.7)
Himbert, 2006 (17) 11/9 7 PLAATO 72  9 NR NR NR NR NR
Sick, 2007 (18) 75/66 24 Watchman 68.5/NR 1.8 55 (73.3) 22 (29.3) NR NR
De Meester, 2008 (19) 10/9 21 PLAATO 73  5 3.3 NR NR NR NR
Park, 2009 (20) 73/73 24 PLAATO 72.7  9.7 2.5 69 (94.5) 26 (35.6) 25 (34.2) NR
Ussia, 2009 (21) 20/18 40 PLAATO þ
Amplatzer
69  8 3.0 18 (45.0) 11 (55) 12 (60.0) 8 (40.0)
Bayard 2010 (9) 180/162 8.6 PLAATO 70  9.7 3.1 150 (83.3) 52 (28.9) 106 (58.8) 75 (41.7)
Lam, 2011 (22) 20/19 12.7 Amplatzer 68  9 2.3 15 (75.0) 9 (45.0) 6 (30.0) 3 (15.0)
Bai, 2012 (23) 58/58 25.9 Watchman 74  9 2.2 NR NR NR NR
Reddy, 2013 (24) 150/142 14.4 Watchman 72.5  7.4 2.8 142 (94.6) 48 (32.0) 61 (40.7) 43 (28.7)
Massumi, 2013 (25) 21/20 11.7 Lariat 73  8 3.2 NR NR 10 (47.6) NR
Urena, 2013 (26) 52/51 20 Amplatzer 74  8 3.0 48 (92.3) 21 (40.4) 32 (61.5) 10 (19.2)
Faustino, 2013 (27) 23/22 12 Amplatzer 70  9 3.2 NR NR NR NR
Danna, 2013 (28) 37/34 12 Amplatzer 73.4  8.3 3.1 28 (75.7) 17 (45.9) 6 (16.2) NR
Bartus, 2013 (11) 89/85 12 Lariat 62  10 1.9 84 (94.3) 9 (10.1) 22 (24.7) 11 (12.4)
Nietlispach, 2013 (29) 152/152 32 Amplatzer þ
others
72  10 NR 114 (75.0) 5 (9.6) 15 (10.0) 6 (3.9)
Helsen, 2013 (30) 25/24 29 PLAATO þ
Amplatzer
73 (49–85) 3.0 19 (76.0) 5 (17.2) 15 (60.0) 6 (24)
Values are n/n, mean, mean  SD, n (%), or median age (range).
CHADS2 ¼ congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack; NR ¼ not reported; PLAATO ¼ Percutaneous Left Atrial Appendage
Transcatheter Occlusion.
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301Physiologically, percutaneous LAA occlusion should offer
the same advantage, and hence, percutaneous closure device
use is an interesting alternative in these patients. However,
there is a paucity of clinical evidence behind the efﬁcacy and
safety of percutaneous LAA occlusion devices. Thus, we
performed the ﬁrst reported systematic review of pooledFigure 3. Forest Plots Depicting Stroke Rates and Composite Neurological Even
(A) Incidence of stroke rate across studies per 100 person-years. (B) Incidence of total
limit; UCL ¼ upper conﬁdence limit.observational studies to compile the available contemporary
evidence.
We estimated the rate of ischemic stroke to be 0.7/100
PY, which is similar to the preliminary PREVAIL trial data,
but less than the rate reported in the PROTECT-AF trial
(10). The estimated stroke rate in our study was either lessts Across Included Studies
neurological events across studies per 100 person-years. LCL ¼ lower conﬁdence
Figure 4. Publication Bias Assessed by Funnel Plot of Standard Error by
Rate for Primary Outcome (Stroke)
Table 3. Adjusted Pooled Rate of Efﬁcacy Outcomes
Event Type
Adjusted
Pooled Rate
95% CI
Lower Limit
95% CI
Upper Limit
Stroke 0.7 0.3 1.1
Transient ischemic attack 0.5 0.1 0.8
Combined neurological events 1.1 0.6 1.6
Values are the incidence rate per 100 person-years.
CI ¼ conﬁdence interval.
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302than or comparable to contemporary strategies utilizing
pharmacotherapeutic anticoagulation, suggesting non-
inferiority of the percutaneous device implantation
(10,32–35). We observed a procedure failure rate of 8.4%
among all 4 implanted devices, which was comparable to the
rate observed in the PROTECT-AF trial (9.1%), CAP
registry (5.7%), and preliminary PREVAIL trial data
available online (4.9%) (1,31). The rate of any complicationTable 2. Adjusted Pooled Rates of Stroke by Device Type, Year,
and Region
Subgroups
Number of
Studies
Adjusted
Stroke Rate
95% CI
Lower Limit
95% CI
Upper Limit
Device type
Amplatzer 3 0.9 0.7 2.4
PLAATO 5 0.7 0 1.5
Watchman 3 0.7 0 1.6
Lariat 2 0.7 0 2.3
Multiple 4 0.6 0 1.3
Year
2005 1 2.3 0 5.4
2006 1 1.9 0 5.6
2007 1 0.4 0 1.4
2008 1 6.1 0 11.6
2009 2 0.4 0 1.3
2010 1 1.7 0 4.1
2011 1 2.4 0 9.2
2012 1 0.8 0 2.4
2013 8 0.7 0.2 1.3
Region
Asia 1 2.4 0 9.2
Europe 9 0.6 0.1 1.1
Multicenter including
United States
4 0.8 0 1.6
United States 2 0.9 0 2.4
Canada 1 0.6 0 2.2
Values are the incidence rate per 100 person-years.
CI ¼ conﬁdence interval; PLAATO ¼ Percutaneous Left Atrial Appendage Transcatheter
Occlusion.was calculated to be 7.1% for all device types and 13.6%
in the Watchman device subgroup, which seemed to be
higher than what was observed in the PROTECT-AF trial
(8.7%), CAP registry (4.1%), and preliminary PREVAIL
trial (4.1%) data. We observed access site complications to
be most common (8.6%), followed by pericardial effusion
(4.1%), which is comparable to the PROTECT-AF trial
data that showed these rates to be 3.5% and 4.8%, respec-
tively. We observed no difference in pooled stroke rates with
various device types, year, or region. There was no difference
in procedural complications by device type. The comparison
of pooled efﬁcacy and safety outcomes by device type has not
been reported in the literature thus far. The pooled rates of
efﬁcacy and safety outcomes of percutaneous LAA occlusion
in observational studies look similar, if not better, than the
PROTECT-AF trial data, indicating that the percutaneous
LAA closure strategy could be a feasible option for stroke
prophylaxis in the real world.
Study limitations. The choice of medical therapy versus
percutaneous LAA closure is dependent on whether the
patient has any contraindication for medical therapy, which
inherently creates a selection bias. Systematic pooling ofTable 4. Periprocedural Adverse Event Rates
Adverse Event
Adjusted
Rate
95% CI
Lower Limit
95% CI
Upper Limit
Access site complications 8.6 6.3 11.7
Pericardial effusion 4.3 3.1 5.9
Pericardial tamponade 2.2 1.4 3.4
Device embolization 3.9 2.7 5.6
Procedural mortality 1.2 0.6 2.2
Need for surgery post-procedure 2.3 1.5 3.6
Procedural failure 8.4 6.6 10.6
All-cause mortality 6.6 5.1 8.4
Any of the above events by device
Overall 16.2 13.8 18.9
Amplatzer, 3 23.5 15.9 33.2
PLAATO, 5 5.4 3.5 8.2
Watchman, 3 13.6 9.7 18.8
Lariat, 2 7.3 2.7 18.3
Multiple, 4 18.8 13.8 25.1
Values are the adjusted rate per 100 procedures.
Abbreviations as in Table 2.
Table 5. Periprocedural Adverse Event Rates by Year
Any Adverse Event
(Year, Number of Studies)
Adjusted
Rate
95% CI
Lower Limit
95% CI
Upper Limit
2005, 1 6.3 3 12.6
2006, 1 9.1 1.3 43.9
2007, 1 22.7 14.6 33.5
2008, 1 4.5 0.3 44.8
2009, 2 5.4 2.3 12.3
2010, 1 4.4 2.2 8.6
2011, 1 15 4.9 27.6
2012, 1 1.7 0.2 11.2
2013, 8 15.8 13.5 20.8
Values are the adjusted rate per 100 procedures.
CI ¼ conﬁdence interval.
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303different observational studies with different baseline char-
acteristics may introduce some imprecision in the results as a
result of heterogeneity. Several studies included in the sys-
tematic analysis have small numbers or have short follow-up
periods. Because of the relative rarity of strokes and safety
outcomes after percutaneous closure, recurrent events are
more likely to be observed in larger study samples with a
longer follow-up period. Another limitation arises from the
fact that the included studies were conducted over different
time periods in different countries utilizing different devices.
It has to be taken into consideration that diagnosis and
treatment modalities, including referral patterns, might have
changed over time. Also, the event rates in observational
studies are under-reported compared with randomized
controlled trials. Despite these limitations, our review seeks
to clarify extensive and confusing published data, by sys-
tematic organization and aggregation of available
information.Figure 5. Comparison of Stroke Prophylaxis Strategies in NVAF
The x-axis represents treatment modalities, and the y-axis represents inci-
dent rate per 100 person-years with 95% conﬁdence intervals. LAA ¼ left atrial
appendage; NVAF ¼ nonvalvular atrial ﬁbrillation; obs ¼ observational trial.Conclusions
In our systematic review and analysis, percutaneous LAA
occlusion for stroke prophylaxis was comparable to historical
controls for adjusted-dose warfarin and comparable to other
anticoagulation agents, providing evidence for device utili-
zation in NVAF patients unable to receive long-term anti-
coagulation. Needless to say, more randomized trials are
required to conclusively compare LAA occlusion to current
medical management strategies.
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